Our biopharmaceutical business aims to become a preferred global biopharmaceutical partner, providing innovative specialty medicines, leading brands, and high-value solutions. Global megatrends such as world population growth and a general increase in life expectancy are bolstering the demand for our products. The aim is to grow at least in line with the global pharmaceutical market.
Innovative drugs are the key to competing in mature markets, which remain the largest and most profitable markets for our products. In addition, we will use customized products and dosage forms to systematically capture the growth potential of emerging markets in order to further expand our leading position in key cardiometabolic diseases mainly based on our General Medicine products such as Glucophage®, Concor® and Euthyrox®.
The business continues to focus on the therapeutic areas of Oncology, Multiple Sclerosis, Fertility and General Medicine.
In Oncology, we launched the Erbitux® Reloaded program, the strategic focus of which is on building on the existing business to expand market share and to ensure market leadership in first-line therapy of metastatic colorectal cancer in patients with KRAS wild-type tumors. Based on the results of the FIRE 3 study as well as further retrospective analyses of pivotal trials, we are emphasizing the importance of offering patients complete testing for RAS status in order to ensure optimum treatment.
In Multiple Sclerosis, the vision is to remain a leader by providing innovative solutions that include drugs, devices and services to help people living with multiple sclerosis. We plan to fully exploit the potential of Rebif®, its top-selling product, in an increasingly competitive multiple sclerosis market and to position it as the best interferon-based therapeutic option for patients who suffer from the relapsing form of the disease.
We intend to further expand our market leadership in Fertility especially by leveraging the comprehensive portfolio of products and life cycle management activities, and by capturing growth opportunities in emerging markets.
In General Medicine, we will focus on further boosting its efforts in emerging markets and enhancing the life cycle management of its products. In addition, we intend to continue to strengthen our current portfolio through suitable partnerships.
China and Brazil are key growth markets for the business. We want to step up our activities in these countries by 2018. At the same time, we intend to further expand its activities in North America. The business is therefore examining potential business models such as alliances, acquisitions of start-ups as well as the launch of new products.